ID   SK-MEL-147
AC   CVCL_3876
SY   SK-Mel-147; SK MEL 147; SKMEL-147; SkMel147; SKMEL147; SK-147; FT-Mel
DR   cancercelllines; CVCL_3876
DR   ChEMBL-Cells; CHEMBL4630606
DR   ChEMBL-Targets; CHEMBL4630706
DR   Cosmic; 685208
DR   Cosmic; 721808
DR   Cosmic; 933133
DR   Cosmic; 1054851
DR   Cosmic; 1122259
DR   Cosmic; 1247853
DR   Cosmic; 1507623
DR   Cosmic; 1669174
DR   Cosmic; 2233673
DR   GEO; GSM555128
DR   GEO; GSM555181
DR   GEO; GSM1507943
DR   GEO; GSM5466407
DR   GEO; GSM5466408
DR   GEO; GSM5466409
DR   Lonza; 1338
DR   PRIDE; PXD007000
DR   Progenetix; CVCL_3876
DR   PubChem_Cell_line; CVCL_3876
DR   Wikidata; Q54953834
RX   PubMed=1716514;
RX   PubMed=6864164;
RX   PubMed=7747814;
RX   PubMed=9598804;
RX   PubMed=17308088;
RX   PubMed=21343389;
RX   PubMed=21725359;
RX   PubMed=24576830;
RX   PubMed=25502142;
RX   PubMed=25728708;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro114Leu (c.341C>T) (p.Ala128Ala, c.384C>T); ClinVar=VCV000077637; Zygosity=Unspecified (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830; PubMed=25728708).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Not specified.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 26
//
RX   PubMed=1716514;
RA   Albino A.P., Davis B.M., Nanus D.M.;
RT   "Induction of growth factor RNA expression in human malignant
RT   melanoma: markers of transformation.";
RL   Cancer Res. 51:4815-4820(1991).
//
RX   PubMed=6864164; DOI=10.1084/jem.158.1.53;
RA   Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F.,
RA   Old L.J.;
RT   "Detection of cell surface and intracellular antigens by human
RT   monoclonal antibodies. Hybrid cell lines derived from lymphocytes of
RT   patients with malignant melanoma.";
RL   J. Exp. Med. 158:53-65(1983).
//
RX   PubMed=7747814;
RA   Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I.,
RA   Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H.,
RA   Cordon-Cardo C., Kamb A.;
RT   "Genetic evidence in melanoma and bladder cancers that p16 and p53
RT   function in separate pathways of tumor suppression.";
RL   Am. J. Pathol. 146:1199-1206(1995).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311;
RA   Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M.,
RA   Torrice C., Hao H.-L., Penland S., Arbiser J.L., Scott G.A., Zhou T.,
RA   Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L.,
RA   Sharpless N.E.;
RT   "Lack of extracellular signal-regulated kinase mitogen-activated
RT   protein kinase signaling shows a new type of melanoma.";
RL   Cancer Res. 67:1502-1512(2007).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//
RX   PubMed=25502142; DOI=10.1038/ncomms6712;
RA   Muller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C.,
RA   Kong X.-J., Possik P.A., Cornelissen-Steijger P.D.M., Geukes Foppen M.H.,
RA   Kemper K., Goding C.R., McDermott U., Blank C., Haanen J.B.A.G.,
RA   Graeber T.G., Ribas A., Lo R.S., Peeper D.S.;
RT   "Low MITF/AXL ratio predicts early resistance to multiple targeted
RT   drugs in melanoma.";
RL   Nat. Commun. 5:5712.1-5712.15(2014).
//
RX   PubMed=25728708; DOI=10.1111/pcmr.12364;
RA   Vogel C.J., Smit M.A., Maddalo G., Possik P.A., Sparidans R.W.,
RA   van der Burg S.H., Verdegaal E.M.E., Heck A.J.R., Samatar A.A.,
RA   Beijnen J.H., Altelaar A.F.M., Peeper D.S.;
RT   "Cooperative induction of apoptosis in NRAS mutant melanoma by
RT   inhibition of MEK and ROCK.";
RL   Pigment Cell Melanoma Res. 28:307-317(2015).
//